The pharmaceutical industry suffered one of its most significant safety reckonings in recent memory when Intercept Pharmaceuticals — now a subsidiary of Italian pharma giant Alfasigma — fully withdrew Ocaliva (obeticholic acid) from the U.S. market between November 14 and 24, 2025. The withdrawal followed years of escalating FDA warnings and a final post-marketing data revelation showing that Ocaliva users faced a staggering 377% higher risk of liver transplant or death compared to patients on placebo. For the approximately 130,000 Americans living with primary biliary cholangitis (PBC) who relied on this drug as a second-line treatment, that statistic represents not just a regulatory failure — it represents lives lost, livers destroyed, and families shattered. Mid-2026 is now the critical window for harmed patients to explore their legal options through an Ocaliva lawsuit before state statutes of limitations begin to close.
What Is Ocaliva and Why Was It Prescribed?
Ocaliva (obeticholic acid) received FDA approval in 2016 as a second-line treatment for primary biliary cholangitis, a rare autoimmune liver disease in which the immune system attacks the bile ducts, causing progressive liver damage. PBC affects roughly 130,000 Americans, the majority of them women, and for patients who could not tolerate or did not respond adequately to ursodiol — the standard first-line treatment — Ocaliva was marketed as a meaningful therapeutic option. Intercept Pharmaceuticals generated billions in Ocaliva revenue during its years on the market, positioning the drug as a breakthrough for an underserved patient population.
What patients and many physicians were not adequately told, according to mounting legal allegations, was that Ocaliva carried an unreasonable and poorly communicated risk of accelerating the very liver damage it was supposed to slow. Patients who were already vulnerable — some with compensated cirrhosis, some without any cirrhosis at all — were allegedly exposed to a drug whose chemical makeup posed an inherent liver toxicity risk that the company failed to adequately disclose or act upon in a timely manner. If you or a loved one took Ocaliva and experienced serious liver complications, understanding the full regulatory timeline is essential context for any potential Ocaliva lawsuit.
The FDA Warning Timeline: A Decade of Escalating Alerts
The regulatory story of Ocaliva is a chronology of warnings that came too late and communications that fell short — a timeline now central to failure-to-warn allegations in litigation. The U.S. Food and Drug Administration issued its first Drug Safety Communication about Ocaliva in 2026’s regulatory history context as early as 2017, just one year after approval, flagging serious concerns about incorrect dosing in patients with advanced liver disease and the resulting risk of serious liver injury.
In 2018, the FDA took the more serious step of adding a Black Box Warning — the most severe warning label available under U.S. drug regulation — after reports emerged of fatal liver injury in Ocaliva patients. A Black Box Warning is intended to alert prescribers and patients to life-threatening risks; critics of Intercept now argue that the company’s response to that warning was inadequate and that marketing practices continued to downplay the severity of risk. By 2021, the FDA restricted Ocaliva’s use specifically in PBC patients with advanced cirrhosis after concluding that the drug could cause serious harm, including liver failure, in that population. Then, in December 2024, the FDA reported the 377% elevated risk finding from post-marketing confirmatory trial data — a number so alarming it prompted the agency to formally request market withdrawal in early 2025. Intercept and Alfasigma complied, completing the withdrawal by late November 2025.
Core Legal Allegations in the Ocaliva Lawsuit
Attorneys investigating Ocaliva claims in 2026 are pursuing several overlapping legal theories against Intercept Pharmaceuticals and its parent company Alfasigma. Understanding these allegations helps potential claimants assess whether their experiences align with what courts are likely to examine. If you suffered a serious outcome after taking Ocaliva, using a medical malpractice calculator can offer an early, general sense of how defective drug injuries are evaluated financially — though every case turns on its own facts.
Failure to Adequately Warn
The central allegation is that Intercept knew or should have known — far earlier than its public disclosures — that Ocaliva posed serious risks of liver decompensation, liver failure, and death, even in patients without advanced cirrhosis. Post-marketing surveillance data allegedly revealed signals of hepatic decompensation that the company was slow to communicate to the FDA, to prescribing physicians, and to patients. Under the learned intermediary doctrine and standard pharmaceutical liability law, drug manufacturers have an ongoing duty to update warnings when new safety information emerges. Plaintiffs argue Intercept repeatedly violated that duty across the period from 2016 through the withdrawal in late 2025.
Design Defect
A second major theory holds that the chemical makeup of obeticholic acid itself posed an unreasonable risk of liver toxicity without a corresponding proven survival benefit — meaning the drug was defectively designed. This claim is bolstered by the FDA’s own post-marketing confirmatory trial data showing no verified survival improvement despite the dramatically elevated risk of liver transplant or death. Intercept twice failed to expand Ocaliva into MASH (metabolic dysfunction-associated steatohepatitis) — in 2020 and 2023 — and cut a third of its workforce before Alfasigma acquired the company, suggesting the scientific community’s confidence in obeticholic acid was eroding even as the drug remained on the PBC market.
Corporate Negligence and Post-Market Surveillance Failures
Plaintiffs also allege broader corporate negligence, arguing that Intercept’s post-market surveillance systems failed to adequately capture and act upon adverse event data. The allegation is that the company prioritized revenue — collecting billions in Ocaliva sales — over patient safety monitoring obligations. Federal law under 21 U.S.C. § 355 imposes ongoing post-marketing obligations on pharmaceutical manufacturers, and attorneys are examining whether Intercept’s internal response to adverse event reports met those statutory requirements.
Ocaliva Lawsuit: Key Statistics at a Glance
| Event / Data Point | Detail | Year |
|---|---|---|
| FDA Approval of Ocaliva | Second-line treatment for primary biliary cholangitis (PBC) | 2016 |
| First FDA Drug Safety Communication | Incorrect dosing in advanced liver disease; serious liver injury risk | 2017 |
| Black Box Warning Added | Reports of fatal liver injury in Ocaliva patients | 2018 |
| FDA Use Restriction | Ocaliva restricted for PBC patients with advanced cirrhosis | 2021 |
| Post-Marketing Risk Data Published | 377% higher risk of liver transplant or death vs. placebo | December 2024 |
| FDA Requests Market Withdrawal | Post-marketing studies linked Ocaliva to severe liver damage and deaths | Early 2025 |
| Full U.S. Market Withdrawal Completed | Intercept/Alfasigma fully withdrew Ocaliva from U.S. market | November 14–24, 2025 |
| Estimated U.S. PBC Patient Population | Approximately 130,000 Americans diagnosed with PBC | Ongoing |
| Litigation Phase (as of mid-2026) | Early intake/investigation — no MDL formed yet; consolidation anticipated | 2026 |
Who Is Eligible to File an Ocaliva Lawsuit in 2026?
As litigation enters its active intake phase in 2026, attorneys are evaluating claims from PBC patients — or their surviving family members — who took Ocaliva and suffered serious harm. CDC data on liver disease outcomes underscores how devastating advanced hepatic events can be, providing important clinical context for damages assessments. The following categories of harm are currently being evaluated for potential case eligibility.
Qualifying Injury Categories
- Liver failure or acute hepatic decompensation occurring during or after Ocaliva use
- Rapid cirrhosis progression in patients who began Ocaliva without advanced cirrhosis
- Hospitalization for liver complications including jaundice, ascites, hepatic encephalopathy, or variceal bleeding
- Liver transplant evaluation or placement on a transplant waiting list following Ocaliva use
- Actual liver transplant necessitated by Ocaliva-associated liver damage
- Wrongful death of a PBC patient whose fatal liver failure is linked to Ocaliva use
Cases involving actual liver transplant, transplant listing, or fatal liver failure are expected to carry the highest settlement and verdict values given the severity and permanence of the harm. Families who lost a loved one to Ocaliva-associated liver failure may use a wrongful death calculator to explore the general financial dimensions of such claims — including lost income, medical expenses, and loss of companionship — while formal legal representation is pursued.
Current State of Ocaliva Litigation in 2026
As of mid-2026, the Ocaliva lawsuit landscape is in its early intake and investigation phase. No Multi-District Litigation (MDL) has been formally established, though legal analysts widely anticipate that as case numbers grow — driven by the November 2025 withdrawal and increased patient awareness — federal courts will consolidate individual cases into an MDL to streamline pre-trial proceedings including discovery and bellwether trials. U.S. Courts data on MDL proceedings reflects how complex pharmaceutical litigation of this scale has historically been managed. The pre-MDL period is critically important: it is when early-filing plaintiffs may have more direct attorney attention and when gathering and preserving medical records, pharmacy records, and treating physician documentation is most straightforward. Statutes of limitations — which vary by state and typically run two to three years from the date of injury or discovery of injury — mean that patients who were harmed should not delay evaluation of their legal options.
Frequently Asked Questions About the Ocaliva Lawsuit
Who can file an Ocaliva lawsuit?
Any patient who was prescribed Ocaliva (obeticholic acid) for primary biliary cholangitis and subsequently suffered serious liver-related harm may be eligible to file an Ocaliva lawsuit. Qualifying harms include liver failure or decompensation, rapid cirrhosis progression, liver transplant evaluation, actual liver transplant, hospitalization for liver complications, or death. Surviving family members of patients who died from Ocaliva-associated liver failure may file wrongful death claims. Cases are evaluated individually based on the duration of Ocaliva use, the severity of harm, and the medical evidence linking the injury to the drug.
Was Ocaliva recalled, and what does the withdrawal mean legally?
Ocaliva was not recalled in the traditional sense — rather, the FDA formally requested that Intercept Pharmaceuticals voluntarily withdraw the drug from the U.S. market following post-marketing data showing a 377% higher risk of liver transplant or death compared to placebo. Intercept and its parent company Alfasigma completed the withdrawal between November 14 and 24, 2025. Legally, an FDA-requested market withdrawal following post-marketing safety data is significant evidence supporting both failure-to-warn and design-defect claims, because it reflects the regulatory agency’s conclusion that the drug’s risks outweighed its benefits even under real-world conditions.
How long do I have to file an Ocaliva lawsuit?
The time you have to file an Ocaliva lawsuit depends on the statute of limitations in your state, which typically ranges from two to three years. Importantly, most states apply a “discovery rule,” meaning the limitations period begins when you knew or reasonably should have known that your injury was linked to Ocaliva — not necessarily the date the harm occurred. Because the drug was only withdrawn from the U.S. market in late 2025 and many patients are only now learning of the connection between their liver complications and Ocaliva, mid-2026 is considered a prime filing window. However, statutes of limitations begin running from different dates for different patients, so prompt legal evaluation is essential.
Is there an Ocaliva MDL, and what does that mean for my case?
As of mid-2026, no Ocaliva Multi-District Litigation (MDL) has been formally established. Litigation is currently in the early intake and investigation phase, with attorneys across the country evaluating and filing individual cases. Legal analysts and mass tort attorneys widely expect that as case volume increases, the Judicial Panel on Multidistrict Litigation will consolidate cases into a single federal MDL, which streamlines pre-trial proceedings like discovery and expert witness challenges while preserving each plaintiff’s right to an individual trial. Filing before an MDL is formed can have strategic advantages, including more individualized case development and attorney attention.
What damages can Ocaliva lawsuit plaintiffs recover?
Plaintiffs in an Ocaliva lawsuit may seek several categories of compensation depending on the nature and severity of their injuries. Economic damages typically include past and future medical expenses (including transplant costs and post-transplant care), lost income and loss of earning capacity, and costs of ongoing liver-related treatment. Non-economic damages include pain and suffering, emotional distress, and loss of quality of life. In wrongful death cases, surviving family members may pursue damages for funeral costs, loss of financial support, and loss of companionship. Cases involving liver transplant or fatal liver failure are expected to carry the highest overall damages values. Punitive damages may also be pursued in cases where evidence demonstrates that Intercept acted with deliberate disregard for patient safety.
This article is provided for informational purposes only and does not constitute legal advice; readers should consult a licensed attorney in their jurisdiction to evaluate their individual legal rights and options.
Related reading: Cardiology Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Related reading: $15.75 Million Verdict: How Wrongful Death Damages Are Calculated When A Nursing Home Ignores Its Own Care Plan
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.